Spleen stiffness mirrors changes in portal hypertension after successful interferon-free therapy in chronic-hepatitis C virus patients

Table 1 Baseline characteristics of included patients

Variable	Overall (n = 134)	CSPH (LSM ≥ 21 kPa) (n = 60)	No CSPH (LSM < 21 kPa) (n = 74)
Age (yr)	60 (51-69)	57 (50.5-65)	61.5 (51-70)
Male	92 (68.7)	42 (70)	50 (67.6)
HCV-genotype
1	95 (70.9)	41 (68.3)	54 (72.5)
2	12 (8.9)	4 (6.7)	8 (10.8)
3	20 (14.9)	11 (18.3)	9 (12.2)
4	7 (5.3)	4 (6.7)	3 (4.5)
Treatment regimen
SOF/RBV	33 (24.6)	10 (16.7)	23 (31.1)
SOF/SMV	29 (21.6)	15 (25)	14 (18.9)
SOF/DCV	38 (28.4)	19 (31.6)	19 (25.6)
SOF/LDV	16 (12)	7 (11.7)	9 (12.2)
Other	18 (13.4)	9 (15)	9 (12.2)
Child Pugh Score
A	115 (85.8)	52 (86.7)	63 (85.1)
B	19 (14.2)	8 (13.3)	11 (14.9)
MELD Score	8 (7-10)	9 (8-10)	8 (7-10)
Spleen Diameter (cm)	14 (12.3-15.5)	14.7 (12.8-15.8)	13.9 (12.1-15)
Laboratory results
Platelets (cells × 109/L)	110 (79-150)	102 (74-132)	134 (92-159)
ALT (U/L)	58 (39-95)	55 (39-84)	60 (38-105)
Bilirubin (mg/dL)	0.9 (0.67-1.29)	1 (0.84-1.52)	0.8 (0.6-1.1)
Albumin (g/dL)	3.8 (3.6-4.1)	3.8 (3.5-4.1)	3.8 (3.6-4.1)
Creatinine (mg/dL)	0.8 (0.7-0.98)	0.8 (0.70-0.96)	0.85 (0.71-1.08)
INR	1.1 (1.06-1.2)	1.17 (1.1-1.21)	1.08 (1.04-1.13)
NITs
SSM (kPa)	58.8 (42.2-75)	69.9 (55.7-75)	46.2 (31.6-63.9)
LSM (kPa)	19.3 (14.1-27)	29.1 (23.9-39.7)	14.6 (12-17)
LSPS	2.78 (1.4-4.94)	5.1 (3.05-7.48)	1.58 (1.09-2.79)

Qualitative data were expressed as number and percentage (%); quantitative data were expressed as median (25%-75% quantiles). ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; CSPH: Clinically significant portal hypertension; DCV: Daclatasvir; HRV: High risk varices; INR: International normalized ratio; LDV: Ledipasvir; LSM: Liver stiffness measurement; LSPS: Liver stiffness to spleen/platelet score; MELD: Model for end-stage liver disease; NITs: Non-invasive tests; RBV: Ribavirin; SMV: Simeprevir; SOF: Sofosbuvir; SVR: Sustained virological response; SSM: Spleen stiffness measurement.